Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Jan 2019

Li Angel, Vigers Tim, Pyle Laura, Zemanick Edith, Nadeau Kristen, Sagel Scott D, Chan Christine L

Abstract excerpt

BACKGROUND: The effects of lumacaftor-ivacaftor therapy on glycemia have not been thoroughly investigated. Continuous glucose monitoring (CGM) provides detailed information about glycemic patterns and detects glucose abnormalities earlier than traditional screening tools for diabetes. METHODS: CGM measures, HbA1c, and oral glucose tolerance test (OGTT) results were collected and within-subject results compared in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzodioxoles

Share to Drug Combinations

Share to Forced Expiratory Volume

Share to Glucose Tolerance Test

Share to Glycated Hemoglobin

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 30104123
DOI: 10.1016/j.jcf.2018.07.010
PMCID: PMC6342629

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.PMID 30104123Read ↗

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.Semantic proximity Read ↗

Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.Semantic proximity Read ↗

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.Semantic proximity Read ↗

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.Semantic proximity Read ↗

Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis.Semantic proximity Read ↗

Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.Semantic proximity Read ↗

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.Semantic proximity Read ↗

Improvements in Glucose Regulation in Children and Young People with Cystic Fibrosis-Related Diabetes following Initiation of Elexacaftor/Tezacaftor/Ivacaftor.Semantic proximity Read ↗

Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.Semantic proximity Read ↗

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.Semantic proximity Read ↗

Clinical and functional course of patients with cystic fibrosis treated with lumacaftor/ivacaftor at a children's hospital. A case series.Semantic proximity Read ↗

An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.